Anaemic results from Animalcare

Animalcare, a veterninary products group, has produced an anaemic set of full-year results with both turnover and profits below last year's levels.

Animalcare, a veterninary products group, has produced an anaemic set of full-year results with both turnover and profits below last year's levels.

For the full year ended June 30th, revenue was down 8.2% at £10.9m with pre-tax profits down 27.5% at £2.1m. The results were in line with the profit warning given earlier this year.

A slight positive was growth in its veterinary medicines business.

Analyst Chris Glasper from House broker N+Singer writes: 'Key to the investment case remains organic growth in the Vet Meds category, with underlying growth continuing at 17%, well ahead of the market.

"The regulatory approval already of the first two of a planned four new products in the year bodes well for sustaining this momentum, and the re-launch of Buprecare in calendar year 13 should help further."

The company reports that current trading is "comfortably above" the same period last year so the hope is that its move up the value chain won't leave investors feeling as sick as a parrot.

CM

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022